1576 related articles for article (PubMed ID: 30141832)
41. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
42. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
[TBL] [Abstract][Full Text] [Related]
43. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
44. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
[TBL] [Abstract][Full Text] [Related]
45. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
[TBL] [Abstract][Full Text] [Related]
46. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
[TBL] [Abstract][Full Text] [Related]
47. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
[TBL] [Abstract][Full Text] [Related]
48. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
49. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
50. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
[TBL] [Abstract][Full Text] [Related]
51. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
[TBL] [Abstract][Full Text] [Related]
52. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
54. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Kotsopoulos J; Huzarski T; Gronwald J; Singer CF; Moller P; Lynch HT; Armel S; Karlan B; Foulkes WD; Neuhausen SL; Senter L; Tung N; Weitzel JN; Eisen A; Metcalfe K; Eng C; Pal T; Evans G; Sun P; Lubinski J; Narod SA;
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27601060
[TBL] [Abstract][Full Text] [Related]
55. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
[TBL] [Abstract][Full Text] [Related]
56. Hormone replacement therapy after surgery for epithelial ovarian cancer.
Saeaib N; Peeyananjarassri K; Liabsuetrakul T; Buhachat R; Myriokefalitaki E
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012559. PubMed ID: 31989588
[TBL] [Abstract][Full Text] [Related]
57. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
58. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in
Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415
[TBL] [Abstract][Full Text] [Related]
59. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
[TBL] [Abstract][Full Text] [Related]
60. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]